Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2023)
关键词
multiple myeloma,innate immunity enhancer,modakafusp alfa
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要